Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 19/20 | 0.54 |
| ▸ | EGFR | P00533 | 10/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480895 | 0.88 | ERBB2 (0.66) | ERBB2EGFRKCNH2 | |
| SCHEMBL4387854 | 0.88 | ERBB2 (0.72) | ERBB2EGFRKCNH2 | |
| SCHEMBL4541716 | 0.88 | ERBB2 (0.72) | ERBB2EGFRKCNH2 | |
| SCHEMBL5474732 | 0.82 | ERBB2 (0.76) | ERBB2EGFRKCNH2 | |
| SCHEMBL4544225 | 0.82 | ERBB2 (0.76) | ERBB2EGFRKCNH2 | |
| SCHEMBL5481081 | 0.82 | ERBB2 (0.66) | ERBB2EGFRKCNH2 | |
| SCHEMBL5401408 | 0.80 | ERBB2 (0.67) | ERBB2EGFRKCNH2 | |
| SCHEMBL4387748 | 0.80 | ERBB2 (0.67) | ERBB2EGFRKCNH2 | |
| SCHEMBL4390213 | 0.80 | ERBB2 (0.67) | ERBB2EGFRKCNH2 | |
| SCHEMBL5469737 | 0.80 | EGFR (0.48) | ERBB2EGFRKCNH2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | ERBB2 1/4885EGFR 3/4885KCNH2 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.